Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for depression in adults with heart failure with reduced ejection fraction
IRCT20111206008307N43Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Dec 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colchicine in major depressive disorder (MDD) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Hamilton depression score, NYHA functional classification and 1 more. Started Dec 2022; status: completed.
02
Drugs
colchicine
03
Conditions
major depressive disorder (MDD)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on IRCT20111206008307N43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111206008307N43.